7 completed, 1 recruiting, 1 terminated. 9 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 7, Recruiting 1, Terminated 1 |
| Phase 1 | 2 | Completed 1, Recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow drospirenone: new trials by email Literature Review of drospirenone trials Research Report on drospirenone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacokinetics of Drospirenone Only Pills: A Pre- and Post-Bariatric Surgery Study Drospirenone - Contraception | Phase 1 / Phase 2 | Recruiting | Chulalongkorn University | 16 | 2024-04-18 | 2026-03-19 |
| Oral Contraceptives for Treating Premenstrual Dysphoric Disorder in Bipolar Disorder Yaz, Placebo - Premenstrual Dysphoric Disorder, Bipolar Disorder | Phase 2 | Completed | St. Joseph's Healthcare Hamilton | 17 | 2023-02-03 | 2024-09-23 |
| E4/DRSP Ovarian Function Inhibition Study 15 mg E4/3 mg DRSP, 20 mcg EE/3 mg DRSP - Prevention of Pregnancy | Phase 2 | Completed | Estetra | 82 | 2017-02-07 | 2023-05-03 |
| "E4/DRSP Endocrine Function, Metabolic Control and Hemostasis Study" 15 mg E4/3 mg DRSP, 30 mcg EE/150 mcg LNG, 20 mcg EE/3 mg DRSP - Contraception, Liver Metabolism | Phase 1 / Phase 2 | Completed | Estetra | 101 | 2016-09-01 | 2018-02-05 |
| A Study to Examine the Safety and Efficacy of Drospirenone and Ethinyl Estradiol (YAZ) Versus Placebo In HS drospirenone and ethinyl estradiol (YAZ), Placebo - Hidradenitis Suppurativa | Phase 2 | Terminated | Massachusetts General Hospital | 4 | 2008-10-01 | 2014-02-10 |
| Cycle Control and Safety of E2-DRSP E2/DRSP (BAY 86-4891) dose 1 (SH T04984E), E2/DRSP (BAY 86-4891) dose 2 (80458739), E2/DRSP (BAY 86-4891) dose 3 (80458755) - Contraceptive, Oral, Hormonal | Phase 2 | Completed | Bayer | 635 | 2008-03-01 | 2015-04-23 |
| A Study to Evaluate Inhibition of Ovulation of Two Oral Estrogen/Progestogen Regimens in Healthy, Young Females Over a Period of 3 Treatment Cycles BAY86-4891 (Estradiol / Drospirenone) - Contraception | Phase 2 | Completed | Bayer | 103 | 2008-02-01 | 2014-12-02 |
| Safety Study of Ethinylestradiol/Drospirenone in Dysmenorrhea DRSP 3 mg/EE 20 µg (13 cycles), DRSP 3 mg/EE 30 µg (6 cycles) - Dysmenorrhea | Phase 2 / Phase 3 | Completed | Bayer | 420 | 2007-02-01 | 2013-01-24 |
| Study to Investigate the Effect of Missed Pills on Follicular Development in Two Application Regimens of SH T 00186 D YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300), Yasminelle (SH T 00186 D) - Contraceptives, Oral | Phase 2 | Completed | Bayer | 105 | 2004-05-01 | 2014-10-13 |
Bipolar Disorder (1) · Dysmenorrhea (1) · Hidradenitis Suppurativa (1) · Obesity (1) · Premenstrual Dysphoric Disorder (1)
Bayer (4) · Estetra (2) · Chulalongkorn University (1) · Massachusetts General Hospital (1) · St. Joseph's Healthcare Hamilton (1)
Netherlands (3) · Germany (2) · Canada (1) · Japan (1) · Thailand (1) · United States (1)
Christine Klipping (2) · Alexandra B Kimball, MD, MPH (1) · Benicio N Frey, MD, MSc,PhD (1) · Punyawee Utaipatanacheep (1)
PMID 10560680, PMID 11245554, PMID 11433905, PMID 12841897, PMID 19461456, PMID 21721590, PMID 2449395, PMID 26232513, PMID 27467196, PMID 28433989, PMID 29634911, PMID 30347490, PMID 31493139, PMID 31758920, PMID 32202076, PMID 32312141, PMID 33008401, PMID 33547015, PMID 3450848, PMID 36103980, PMID 36316023, PMID 37365881, PMID 37523477, PMID 37544572, PMID 7068318, PMID 7500749, PMID 7500750, PMID 9673838
2016 (2)